Please assess the completion status of the following clinical trial:

Trial Title: Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Participants must meet all of the following criteria to be considered eligible for entry into the study:~1. At least 18 years of age~2. Presenting with clinical signs of either primary or secondary syphilis; or with early latent syphilis and documented negative serology within the past 12 months.~3. Positive syphilis serology (reactive CMIA and TP-PA) with a defined RPR titer at the time of diagnosis and enrolment~4. Able to provide informed consent~5. Able to communicate in either English of French~6. Able to return for follow-up~Exclusion Criteria:~Participants are not eligible to participate in the study if any of the following conditions are met:~1. Diagnosis of late latent syphilis, tertiary syphilis, or syphilis of unknown duration~2. Allergy to penicillin~3. Diagnosis of neurosyphilis requiring treatment with intravenous penicillin~4. Treatment with doxycycline or ceftriaxone~5. Treatment with more than one intramuscular dose of benzathine penicillin G~6. Treatment with any antibiotics within the 6 weeks prior to enrolment~7. Pregnant or breastfeeding~8. Any immune modulating therapy~9. Patient is unable or unwilling to return for blood sampling at 3 and 7 days post treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Syphilis Patients (Type: None): Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.

Based on this trial design, predict the completion outcome and termination type (if applicable).